25 July 2024 in Farmacja Polska
Przedmiot badań: Prezentowana praca omawia wpływ polimorfizmu genetycznego na farmakokinetykę i farmakodynamikę leków zwiotczających mięśnie stosowanych podczas znieczulenia ogólnego. W naszej pracy przyglądamy się działaniu powszechnie stosowanych w anestezjologii leków, takich jak sukcynylocholina, miwakurium i rokuronium. Celem badania jest wykazanie zależności pomiędzy ekspresją poszczególnych genów kodujących enzymy modyfikujące działanie tych leków a wpływem genetyki na ich eliminację z organizmu. Cel pracy: Celem prezentowanej pracy jest jak najlepsze dostosowanie i dobór leków "szytych na miarę" dla poszczególnych pacjentów, co jest szczególnie istotne ze względu na możliwość uniknięcia powikłań związanych ze stosowaniem powszechnie używanych leków zwiotczających mięśnie. Materiał i metody: Przy pisaniu artykułu korzystaliśmy z artykułów naukowych dostępnych w popularnych źródłach, takich jak PubMed i Google Scholar. Bibliografia w dużej mierze składa się z publikacji z ostatnich pięciu lat. Wyniki i wnioski: Przedstawione w pracy przykłady polimorfizmów DNA oraz opisane częste działania niepożądane leków stosowanych w znieczuleniu ogólnym wskazują na istotną rolę farmakogenetyki w doborze najwłaściwszego leku dla poszczególnych pacjentów podczas zabiegu operacyjnego. Jak staraliśmy się wykazać, ma to znaczący wpływ na lepsze wyniki leczenia i pomaga zminimalizować ewentualne działania niepożądane. Znaczenie badania dla współczesnej praktyki: Nasze badanie jest jednym z nielicznych, które zbiera wszystkie dostępne dane na temat powiązań genetycznych z farmakodynamiką i farmakokinetyką leków zwiotczających mięśnie. W dzisiejszych czasach, gdy znieczulenie ogólne stosowane jest częściej niż kiedykolwiek wcześniej, znajomość genetyki pacjenta mogłaby pomóc przewidzieć sposób działania najpopularniejszych leków zwiotczających mięśnie i dostosować znieczulenie indywidualnie dla pacjenta. To z kolei mogłoby poprawić komfort pacjenta podczas operacji i zmniejszyć częstość występowania działań niepożądanych związanych ze znieczuleniem ogólnym.
11 April 2024 in Medical Science Pulse
Background: Mivacurium is the shortest-acting non-depolarizing neuromuscular blocking agent (NMBA) with a rapid onset of action that is mainly used for short procedures. Despite the fact that mivacurium has a very favorable average 6-minute recovery index after its infusion in comparison to the approximately 15–30 minutes for atracurium, mivacurium is still not really popular among practicing anesthesiologists. Many new studies showing the potential further benefits of implementing mivacurium into daily practice are still being published. Aim of the Study: This study aimed to focus on spreading the common knowledge about the detailed pharmacokinetic and pharmacodynamic properties of mivacurium as a medication that has yet to be used widely by practicing anesthesiologists. Material and methods: The literature review was conducted using the common sources of original articles such as PubMed and Google Scholar from 1975 to September 2022. Results: Based on the literature review, we observed that Mivacurium at a dosage of 6μg produces a lower impact on hemodynamics, shorter intubation and extubation times, faster postoperative recovery, absence of the accumulation of neuromuscular blockade, higher safety, and no significant increase in allergic related adverse events in comparison with other NMBAs.Conclusions: Mivacurium is a muscle relaxant medication that is particularly suited for short-lasting surgical procedures. However, it is important to remember that existing mutations in the butyrylcholinesterase enzyme (BChE) may prolong the effect of the neuromuscular blockade due to significantly reducing plasma cholinesterase activity. Therefore, it is advised to stay cautious during its use as more research needs to be done to be able to thoroughly assess the potential advantages and disadvantages of mivacurium introduction in particular patients
14 July 2025 in Medical Science Pulse
Background: There are significant differences in the anatomy and physiology of children compared to adults, which have important implications for anesthesia. The incidence of anesthetic complications is higher in children than in adults. Newborns, infants, and children undergoing emergency procedures or those with severe comorbidities are particularly at increased risk for potential complications.Aim of the study: The aim of this work is to identify anesthetic complications associated with the cardiovascular system, along with their management.Material and methods: This work is based on both available literature and the authors' experience. The search process identified relevant articles using valid keywords across electronic databases, including Embase, PubMed, Scopus, Web of Science, and the Cochrane Library. In total, 29 articles published between 1994 and 2022 were deemed eligible for inclusion in our review.Results: Common cardiovascular complications in pediatric anesthesia include sudden cardiac arrest (SCA), hypotension, bradycardia, and arrhythmias. Neonates and infants under 12 months of age have the highest rate of adverse events, both intraoperatively and in the postanesthesia recovery room. Conclusions: The foundation of safe pediatric anesthetic practice consists of careful preoperative assessment, adherence to strict pediatric anesthesia protocols, and the presence of an experienced team. Moreover, only anesthesiologists well-trained in pediatric care should be entrusted with the management of pediatric patients.
31 August 2026 in Medical Science Pulse
Background: Cisatracurium is a non-depolarizing neuromuscular blocking agent (NMBA) with an intermediate duration of action, used both in anesthesia and in intensive care units. Its elimination primarily occurs via Hofmann elimination, making it independent of liver and kidney function. Cisatracurium has approximately three times greater neuromuscular blocking potency and a more favorable hemodynamic profile than atracurium. Despite these advantages, cisatracurium is not the first choice for procedures requiring rapid endotracheal intubation due to its relatively long onset time.Aim of the study: The aim of this study was to discuss the role of cisatracurium in anesthesia, compare its properties with those of other muscle relaxants, and identify its advantages and limitations.Material and methods: A literature review was performed involving a search for original studies in PubMed and Google Scholar published between 1995 and 2024.Results: Thirteen clinical studies met the inclusion criteria. Cisatracurium demonstrated a stable hemodynamic profile, predictable neuromuscular blockade, and favorable safety characteristics. Effective intubation conditions were most commonly achieved with doses of 0.2–0.3 mg/kg. Elderly patients exhibited a prolonged onset and duration of action. Compared with rocuronium-based regimens, cisatracurium combined with neostigmine was associated with slower recovery and a higher incidence of some postoperative pulmonary complications.Conclusions: Cisatracurium is an effective and safe muscle relaxant, particularly in situations requiring hemodynamic stability. Its Hofmann elimination makes it suitable for use in patients with renal and hepatic failure. However, its delayed onset of action limits its use in procedures requiring rapid intubation. Further studies are needed to evaluate the effects of cisatracurium on postoperative complications and its role in specific patient groups.